Ovation Science Secures New Canadian Patent; Strengthening IP Position and Expanding Commercial Opportunities for Topical Cannabis Products

Executive Summary

• Ovation Science Inc. announced the issuance of a new Canadian patent covering its proprietary transdermal CBD/THC formulations, expanding its IP portfolio to both the U.S. and Canada.
• The patent strengthens Ovation’s defensible position and enhances its ability to pursue exclusive licensing agreements, strategic partnerships, and product commercialization in two of the world’s largest regulated cannabis markets.
• Management highlighted that the company already has four licensees and expects the expanded IP protection to drive recurring, non‑dilutive revenue growth throughout 2026.

Key Details

• Patent title: “Composition and method for transdermal delivery of cannabidiol (CBD) and delta9‑tetrahydrocannabinol (THC)”.
• Covers proprietary topical/transdermal formulations powered by Ovation’s Invisicare® drug‑delivery technology.
• Expands Ovation’s IP portfolio, which now includes patents in the United States and Canada.
• Company cites laboratory data showing CBD bioavailability up to 82%, far exceeding competing products (2–3%).
• Management quote – Terry Howlett, President: “Securing Canadian patent protection strengthens our defensible IP position… and expands our ability to generate recurring, non‑dilutive revenue through licensing and branded product partnerships.”
• Current licensing base: four licensees in place.
• Anticipated impact: enhanced attractiveness to potential licensees and partners; supports premium product positioning and long‑term brand loyalty.
• Potential growth pathways: expansion of Invisicare® platform into wellness, pharmaceutical, beauty, and other transdermal categories beyond cannabis.

Notable Quotes

“This patent represents a significant value‑creation milestone for Ovation, our shareholders and licensees,” – Terry Howlett, President, Ovation Science Inc.